Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' [MSNBC.com]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: MSNBC.com
A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.Tom Little | ReutersCopenhagen, DENMARK —CEO Lars Fruergaard Jørgensen on Thursday acknowledged the sharp share price reaction after two consecutive late-stage trials showed underwhelming weight reduction versus the company's own targets, but said he nevertheless remained "encouraged" by the drug's weight loss profile."I'm very confident about CagriSema," he told shareholders at the firm's Annual General Meeting in Copenhagen, Denmark."It will be an important product for us."watch nowVIDEO3:1903:19Novo Nordisk says compounded drugs are hurting Wegovy salesSquawk Box EuropeHeadline results from a REDEFINE-2 late-stage trialreleasedA prior late-stage trialpublishedBoth results wiped significant value from Novo's share price as investors' hopes of finding a superior alternative to the company's existing Wegovy injection and rivalEli Lily'sStock Chart IconStock c
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- ?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]Yahoo! Finance
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website